• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

感染和接种疫苗后对 SARS-CoV-2 变体的抗体的广度和中和能力增强:瑞士南部儿科患者的血清学监测研究。

Increased breadth and neutralization of antibodies against SARS-CoV-2 variants after infection and vaccination: A serosurveillance study in pediatric patients of Southern Switzerland.

机构信息

Institute of Pediatrics of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.

Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

出版信息

Eur J Pediatr. 2024 Mar;183(3):1425-1434. doi: 10.1007/s00431-023-05400-7. Epub 2024 Jan 4.

DOI:10.1007/s00431-023-05400-7
PMID:38175262
Abstract

Little information is available about the nature of the immune response in children after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or vaccination. The aim of this study is to define the seroprevalence and the features of the antibody response in children of Southern Switzerland during the different waves of Coronavirus Disease 2019 (COVID-19) pandemic. By analyzing 756 sera collected from children aged 0 to 16 years admitted to the Institute of Pediatrics of Southern Switzerland during the prepandemic period (before March 2020) and the first four pandemic waves (between March 2020 and June 2022), we investigated binding titers, cross-reactivity, and neutralizing properties of the serum antibodies against SARS-CoV-2 variants. Seroprevalence varied from 6% during the first wave to 14% and 17% during the second and third waves, respectively, peaking at 39% during the fourth wave. The 96 seropositive cases were mostly asymptomatic (42.7%) or showed mild (20.8%) to moderate (32.3%) symptoms. Moderate symptoms and close contact with COVID-19-positive individuals were associated with a higher infection risk (P < 0.001). The antibody response was mainly driven by IgG directed to the receptor-binding domain (RBD) of Wuhan-1 SARS-CoV-2 Spike (S). Children infected in the first three waves produced antibodies with up to 11-fold and 5.5-fold reduction in binding and neutralizing titers, respectively, against different SARS-CoV-2 variants, including Beta, Delta, and Omicron BA.1, BA.2, and BA.5. Such reductions were less pronounced in children infected during the fourth wave, who showed the highest frequency and titers of neutralizing antibodies against the same variants. Compared to infection, vaccination with a Wuhan-1-based messenger RNA (mRNA) vaccine induced higher and heterogenous levels of antibodies cross-reacting to the different SARS-CoV-2 variants analyzed.   Conclusions: Despite the high burden of COVID-19 in Southern Switzerland, we observed an initial low seroprevalence of SARS-CoV-2 in children, which increased in the later waves. The antibody response was poor in the first three waves and improved in the fourth wave, when children produced higher levels of neutralizing antibodies after vaccination or infection with Delta and/or Omicron variants. What is Known: • Children were marginally affected by the initial SARS-CoV-2 variants. • The number of infected and hospitalized children increased after the appearance of the Omicron variants. What is New: • Seroprevalence of SARS-CoV-2 in children of Southern Switzerland increased overtime. • Children produced higher levels of neutralizing antibodies after vaccination or infection with Delta and/or Omicron variants in the fourth wave compared to children infected in the first three waves.

摘要

关于儿童在严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 感染或接种疫苗后的免疫反应性质,目前所知甚少。本研究旨在定义瑞士南部儿童在 2019 年冠状病毒病 (COVID-19) 大流行的不同波次中,血清阳性率和抗体反应特征。通过分析在流行前时期(2020 年 3 月之前)和前四个大流行波次(2020 年 3 月至 2022 年 6 月期间)期间,因感染而入住瑞士南部小儿科研究所的 0 至 16 岁儿童的 756 份血清,我们研究了血清对 SARS-CoV-2 变体的结合滴度、交叉反应性和中和特性。血清阳性率在第一波次期间为 6%,第二波次和第三波次期间分别为 14%和 17%,在第四波次期间达到 39%的峰值。96 例血清阳性病例大多无症状(42.7%)或表现为轻症(20.8%)至中症(32.3%)。中症和与 COVID-19 阳性个体的密切接触与更高的感染风险相关(P<0.001)。抗体反应主要由针对武汉-1 SARS-CoV-2 Spike(S)受体结合域(RBD)的 IgG 驱动。在前三个波次中感染的儿童产生的抗体,与不同的 SARS-CoV-2 变体(包括 Beta、Delta 和 Omicron BA.1、BA.2 和 BA.5)的结合和中和滴度分别降低了 11 倍和 5.5 倍。在第四波次中感染的儿童的这种降低程度不太明显,他们表现出针对相同变体的中和抗体的最高频率和滴度。与感染相比,接种基于武汉-1 的信使 RNA(mRNA)疫苗诱导了对分析的不同 SARS-CoV-2 变体具有更高和异质水平的交叉反应抗体。结论:尽管 COVID-19 在瑞士南部的负担很高,但我们观察到儿童 SARS-CoV-2 的初始血清阳性率较低,在后期波次中有所增加。在前三个波次中,抗体反应较差,在第四波次中有所改善,当儿童接种武汉-1 基于 mRNA 的疫苗或感染 Delta 和/或 Omicron 变体后,产生了更高水平的中和抗体。已知内容:• 儿童受 SARS-CoV-2 初始变体的影响较小。• 感染和住院的儿童人数在 Omicron 变体出现后增加。新内容:• 瑞士南部儿童的 SARS-CoV-2 血清阳性率随时间推移而增加。• 与前三个波次中感染的儿童相比,在第四波次中接种或感染 Delta 和/或 Omicron 变体后,儿童产生了更高水平的中和抗体。

相似文献

1
Increased breadth and neutralization of antibodies against SARS-CoV-2 variants after infection and vaccination: A serosurveillance study in pediatric patients of Southern Switzerland.感染和接种疫苗后对 SARS-CoV-2 变体的抗体的广度和中和能力增强:瑞士南部儿科患者的血清学监测研究。
Eur J Pediatr. 2024 Mar;183(3):1425-1434. doi: 10.1007/s00431-023-05400-7. Epub 2024 Jan 4.
2
Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults.2022 年夏末挪威的 SARS-CoV-2 抗体特征:所有年龄段的血清阳性率都很高,儿童中主要为奥密克戎感染模式,成人中为混合免疫。
BMC Infect Dis. 2024 Aug 20;24(1):841. doi: 10.1186/s12879-024-09670-w.
3
SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia.埃塞俄比亚霍瓦萨地区学龄儿童中的 SARS-CoV-2 感染和 mRNA 疫苗诱导的体液免疫。
Front Immunol. 2023 Jun 15;14:1163688. doi: 10.3389/fimmu.2023.1163688. eCollection 2023.
4
Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.野生型 SARS-CoV-2 中和抗体的免疫活性会随着时间推移和变异株的不同而降低,但与诊断检测有很好的相关性。
Front Immunol. 2023 Feb 8;14:1055429. doi: 10.3389/fimmu.2023.1055429. eCollection 2023.
5
Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.奥密克戎变异株疫苗突破性感染诱导针对 SARS-CoV-2 奥密克戎 BA.1 的交叉中和反应优于单独感染。
Int J Mol Sci. 2022 Jul 12;23(14):7675. doi: 10.3390/ijms23147675.
6
Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study.瑞士日内瓦奥密克戎BA.2浪潮后抗SARS-CoV-2抗体的血清流行率和交叉变异中和能力:一项基于人群的研究
Lancet Reg Health Eur. 2023 Jan;24:100547. doi: 10.1016/j.lanepe.2022.100547. Epub 2022 Dec 1.
7
Anti-SARS-CoV-2 serology based on ancestral RBD antigens does not correlate with the presence of neutralizing antibodies against Omicron variants.基于原始受体结合域(RBD)抗原的抗严重急性呼吸综合征冠状病毒2(SARS-CoV-2)血清学与针对奥密克戎变异株的中和抗体的存在不相关。
Microbiol Spectr. 2025 Jan 7;13(1):e0156824. doi: 10.1128/spectrum.01568-24. Epub 2024 Nov 20.
8
Diversified humoral immunity and impacts of booster vaccines: SARS-CoV-2 antibody profile and Omicron BA.2 neutralization before and after first or second boosters.多元化的体液免疫和加强疫苗的影响:初次或第二次加强针前后 SARS-CoV-2 抗体特征和奥密克戎 BA.2 的中和作用。
Microbiol Spectr. 2024 Oct 3;12(10):e0060524. doi: 10.1128/spectrum.00605-24. Epub 2024 Aug 20.
9
Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.感染或接种疫苗后针对 SARS-CoV-2 奥密克戎变异株的抗体亲合力和中和反应。
J Immunol Res. 2022 Aug 31;2022:4813199. doi: 10.1155/2022/4813199. eCollection 2022.
10
Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.接种疫苗和奥密克戎 BA.1/BA.2 感染恢复期增强了针对 BA.4/5 的系统性但非黏膜免疫。
Microbiol Spectr. 2023 Jun 15;11(3):e0516322. doi: 10.1128/spectrum.05163-22. Epub 2023 Apr 26.

本文引用的文献

1
Prevalence of SARS-CoV-2 infection and impact of vaccination in dialysis patients over two years of the pandemic.新冠疫情两年期间透析患者中新型冠状病毒2型感染的患病率及疫苗接种的影响
J Nephrol. 2023 Dec;36(9):2665-2667. doi: 10.1007/s40620-023-01754-1. Epub 2023 Sep 13.
2
Neutralization, effector function and immune imprinting of Omicron variants.奥密克戎变异株的中和作用、效应功能和免疫印迹。
Nature. 2023 Sep;621(7979):592-601. doi: 10.1038/s41586-023-06487-6. Epub 2023 Aug 30.
3
Incidence, Risk, and Severity of SARS-CoV-2 Reinfections in Children and Adolescents Between March 2020 and July 2022 in Serbia.
2020 年 3 月至 2022 年 7 月塞尔维亚儿童和青少年中 SARS-CoV-2 再感染的发生率、风险和严重程度。
JAMA Netw Open. 2023 Feb 1;6(2):e2255779. doi: 10.1001/jamanetworkopen.2022.55779.
4
SARS-CoV-2 seroprevalence in children worldwide: A systematic review and meta-analysis.全球儿童中新型冠状病毒2型血清流行率:一项系统评价与荟萃分析。
EClinicalMedicine. 2023 Feb;56:101786. doi: 10.1016/j.eclinm.2022.101786. Epub 2022 Dec 28.
5
Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白特异性记忆B细胞的成熟增强了对病毒逃逸的抵抗力。
iScience. 2023 Jan 20;26(1):105726. doi: 10.1016/j.isci.2022.105726. Epub 2022 Dec 5.
6
High antibody levels and reduced cellular response in children up to one year after SARS-CoV-2 infection.新冠病毒感染后一年内儿童体内抗体水平高且细胞反应降低。
Nat Commun. 2022 Nov 28;13(1):7315. doi: 10.1038/s41467-022-35055-1.
7
SARS-CoV-2 seroepidemiology in paediatric population during Delta and Omicron predominance.德尔塔和奥密克戎变异株流行期间儿科人群中 SARS-CoV-2 的血清流行病学。
Epidemiol Infect. 2022 Oct 19;150:e177. doi: 10.1017/S0950268822001601.
8
Long-Term Antibody Response to SARS-CoV-2 in Children.儿童对 SARS-CoV-2 的长期抗体反应。
J Clin Immunol. 2023 Jan;43(1):46-56. doi: 10.1007/s10875-022-01355-w. Epub 2022 Sep 19.
9
Antibody response against SARS-CoV-2 variants of concern in children infected with pre-Omicron variants: An observational cohort study.儿童感染前奥密克戎变异株后对关注的 SARS-CoV-2 变异株的抗体反应:一项观察性队列研究。
EBioMedicine. 2022 Sep;83:104230. doi: 10.1016/j.ebiom.2022.104230. Epub 2022 Aug 18.
10
SARS-CoV-2 infection in children and implications for vaccination.儿童感染 SARS-CoV-2 及其对疫苗接种的影响。
Pediatr Res. 2023 Apr;93(5):1177-1187. doi: 10.1038/s41390-022-02254-x. Epub 2022 Aug 15.